MBA Ashizawa - Bio Path Development Research
| BPTH Stock | USD 0.80 0.01 1.27% |
Executive
MBA Ashizawa is Development Research of Bio Path Holdings
| Address | 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401 |
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.4003) % which means that it has lost $1.4003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6618) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -4.74. The Bio Path's current Return On Capital Employed is estimated to increase to -11.45. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Mark Rubinstein | Achieve Life Sciences | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Michael Graham | Benitec Biopharma Ltd | N/A | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| Kevin Shaw | NextCure | 49 | |
| Udayan MD | NextCure | N/A | |
| Jaime Xinos | Achieve Life Sciences | N/A | |
| Claudia Kloth | Benitec Biopharma Ltd | N/A | |
| Sourav Kundu | NextCure | 63 | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| Craig Donnelly | Achieve Life Sciences | N/A | |
| Charles Garner | Aileron Therapeutics | 48 | |
| ScD MD | Moleculin Biotech | 72 | |
| MD FACC | Capricor Therapeutics | 68 | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| MD FACP | Moleculin Biotech | 72 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -3.66 | ||||
| Return On Asset | -1.4 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| MBA Ashizawa, Development Research | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Victoria Rac, Regulatory Consultant | ||
| Anthony Price, Accounting Finance | ||
| Douglas Morris, Co-Founder and Director | ||
| MBA MBA, Development Research |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.66 | ||||
| Return On Asset | -1.4 | ||||
| Current Valuation | 2.86 M | ||||
| Shares Outstanding | 4.31 M | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 77.76 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.